Pharmaceutical Sciences


Repurposing of Umifenovir against COVID-19


Life Sciences & Biotechnology, Pharmaceutical Sciences, COVID-19 Technology

Focus Area:

Development of Repurposed Drugs for COVID-19

Company Transferred:

Medizest Pharmaceuticals Pvt. Ltd., Goa

Developing Agency:

Central Drug Research Institute (CSIR-CDRI), Lucknow

Technology Readiness Index:

Technology development
Website Link :

Brief Description

Description :

An economical process technology has been developed using indigenously available key starting materials. CSIR-CDRI has received the permission from Central Drugs Standard Control Organization for conducting the Phase III clinical trial with Umifenovir entitled "Randomised, double blind, placebo controlled trial of efficacy, safety and tolerability of Antiviral drug Umifenovir vs standard care of therapy in non-severe COVID-19 patients.”

Related Technologies